Post Chikungunya Arthritis: A Real Diagnostic and Therapeutic Challenge
| Autor: | Ashok Kumar, Mohammad Shariq Mukarram, Syeda Urooj Riaz, Mohammad Mashood Iqbal, Amir Riaz, Muhammad Ishaq Ghauri |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Inflammatory arthritis Population lcsh:Medicine Arthritis non-steroidal antiinflammatory disease modifying anti rheumatic drugs (dmards) medicine.disease_cause Health Professions (miscellaneous) 03 medical and health sciences 0302 clinical medicine disease activity score 28 (das 28) drugs (nsaids) Internal medicine medicine Outpatient clinic 030212 general & internal medicine Chikungunya chikungunya (chik) skin and connective tissue diseases education 030203 arthritis & rheumatology education.field_of_study business.industry lcsh:R medicine.disease Rheumatology arthritis Rheumatoid arthritis business Case series |
| Zdroj: | Journal of the Dow University of Health Sciences, Vol 14, Iss 1, Pp 22-26 (2020) |
| ISSN: | 2410-2180 1995-2198 |
| DOI: | 10.36570/jduhs.2020.1.890 |
| Popis: | Objective: To evaluate the response of disease modifying anti rheumatic drugs (DMARDs) on patients diagnosed with post chikungunya inflammatory arthritis attending outpatient department of Rheumatology, Jinnah Medical College Hospital, Karachi, Pakistan. Methods: This prospective case series study was conducted at Rheumatology clinic of Jinnah Medical College Hospital in Karachi, Pakistan from January – June 2017 after a serious Chikungunya outbreak in November 2016. All patients diagnosed with Chikungunya viral fever who had joint pain refractory to non-steroidal anti-inflammatory drugs (NSAIDs) were evaluated. All eligible patients were given a trial of DMARDs along with systemic steroids (tapering) for 6 months. Clinical response and inflammatory burden were evaluated using the Disease Activity Score (DAS 28). Results: Of 112 patients, more than half the population, 65/112 (58%) was in acute flare of disease at the beginning of study and interestingly not a single patient had high disease activity (DAS >5.1) at the end of 6 months. Patients who went into disease remission were able to lead a pain free life, while those with a relatively higher DAS28 were still struggling with the disease. The overall response to the therapy was eloquent. None of the patient remained in active flair by the end of 6 months. The mean DAS significantly decline at 6 months as compared to the baseline DAS (2.79 ±0.89 vs. 4.96 ±1.11 respectively, p-value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|